Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397367 | 0.99 | HTR2A (0.49) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 | |
| SCHEMBL29550444 | 0.97 | HTR2A (0.50) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 | |
| SCHEMBL6816689 | 0.94 | SIGMAR1 (0.52) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 | |
| SCHEMBL25184955 | 0.88 | HTR2A (0.47) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 | |
| SCHEMBL313620 | 0.86 | SIGMAR1 (0.51) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 | |
| SCHEMBL6820153 | 0.85 | MAPT (0.49) | HTR2ABCL9CTNNB1CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL16694512 | 0.85 | SIGMAR1 (0.50) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 | |
| Hydrochloric Acid SCHEMBL16694856 | 0.84 | ALDH1A1 (0.47) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 | |
| SCHEMBL21097203 | 0.84 | HTR2A (0.51) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 | |
| SCHEMBL25635954 | 0.84 | HTR2A (0.48) | HTR2ASIGMAR1BCL9CTNNB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| CN-1953975-A | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-04-25 | — | — | CN | disclosed |
| EP-1697351-A1 | 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058883-A1 | 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | HTR2A 16/4885SIGMAR1 353/4885BCL9 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.